Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-31001074; ketoconazole · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| JNJ-31001074; ketoconazole | DRUG | - |
Inclusion Criteria: * healthy volunteer between the ages of 18-55 * if a woman, must be of non childbearing potential (ie, post menopausal or surgically sterile) and have a negative pregnancy test * body mass index between 18-30 * body weight greater than or equal to 50 kilograms * blood pressure b...
JNJ-31001074 is an investigational small molecule developed by Johnson & Johnson. It has been studied in a Phase 1 drug interaction trial in healthy volunteers, and no approved indication has been disclosed for it. The compound remains in early clinical development.
JNJ-31001074 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 drug interaction study of the compound in healthy volunteers.
JNJ-31001074 is in Phase 1 clinical development. Its only listed trial, NCT00915746, was a Phase 1 drug interaction study that has been completed. The drug is investigational and has not been approved for any indication.
JNJ-31001074 has been evaluated in one clinical trial, NCT00915746, titled A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers. The Phase 1 study enrolled 14 healthy participants, was uncontrolled, and is now completed.
No. JNJ-31001074 and ketoconazole are separate compounds. Ketoconazole was used as the interacting drug in the Phase 1 study NCT00915746, which examined how the two agents affect each other in healthy volunteers. JNJ-31001074 is the investigational agent developed by Johnson & Johnson.
Trial NCT00915746 studied drug interactions and pharmacokinetics of JNJ-31001074 when given with ketoconazole in healthy volunteers. The Phase 1 study enrolled 14 participants aged 18 years and older, was uncontrolled, and has been completed.